Each dot is one of the 15 Gene and Cell Therapy stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 16.1% and the median P/E 20.66. Pinned to the edge: 2 outliers on X and 1 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | JNJJohnson & Johnson | 7.8% | 39.79 | $640.38B | Pharmaceuticals |
| 2 | AZNAstrazeneca | 9.4% | 25.41 | $265.42B | Pharmaceuticals |
| 3 | VRTXVertex Pharmaceuticals | 10.2% | 29.65 | $130.61B | Biotechnology |
| 4 | BMYBristol Myers Squibb | 3.1% | 13.50 | $125.30B | Pharmaceuticals |
| 5 | UTHRUnited Therapeutics | 2.5% | 19.15 | $25.10B | Pharmaceuticals |
| 6 | NBIXNeurocrine Biosciences | 34.4% | 20.66 | $14.58B | Pharmaceuticals |
| 7 | BMRNBiomarin Pharmaceutical | 11.2% | 147.34OUT | $10.75B | Biotechnology |
| 8 | KRYSKrystal Biotech | 22.6% | 38.19 | $9.22B | Gene and Cell Therapy |
| 9 | TGTXTg Therapeutics | 76.1% | 17.38 | $7.67B | Biotechnology |
| 10 | VCELVericel | 23.0% | 91.63 | $2.22B | Gene and Cell Therapy |
| 11 | LKFTLakefront Biotherapeutics | 179.7%OUT | 3.02 | $2.09B | Biotechnology |
| 12 | PCRXPacira BioSciences | 5.7% | 98.10 | $1.44B | Pharmaceuticals |
| 13 | MGTXMeiraGTx Holdings | 957.3%OUT | 9.75 | $842.88M | Gene and Cell Therapy |
| 14 | AGENAgenus | 30.5% | 2.83 | $259.60M | Biotechnology |
| 15 | FBIOFortress Biotech | 16.1% | 7.11 | $59.45M | Biotechnology |
Among Gene and Cell Therapy stocks, the largest companies growing revenue faster than the median (16.1%) while trading below the median P/E (20.66) are Tg Therapeutics (TGTX), Lakefront Biotherapeutics (LKFT), MeiraGTx Holdings (MGTX), Agenus (AGEN) and Fortress Biotech (FBIO). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), Astrazeneca (AZN), Vertex Pharmaceuticals (VRTX), Biomarin Pharmaceutical (BMRN) and Pacira BioSciences (PCRX).
The median P/E across the 15 Gene and Cell Therapy stocks plotted is 20.66, with the middle half between 11.62 and 38.99.
The median is 16.1%, with the middle half between 8.6% and 32.4%.
The rank correlation (Spearman) is -0.42, a moderate negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 2 companies are outliers on Revenue Growth (1y) (TTM) and 1 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.